Debio 1562M: A First-in-Class CD37-Targeting ADC for the Treatment of Acute...
Acute Myeloid Leukemia (AML) is the most common, highly aggressive, and genetically heterogeneous hematologic malignancy, characterized by the uncontrolled proliferation of immature myeloid cells in...
View ArticleClik here to view.
Conjugation Technologies in ADCs: Innovations, Challenges, Clinical Impact,...
Antibody–drug conjugates (ADCs) have transformed targeted cancer therapy by enabling the selective delivery of cytotoxic agents to tumor cells, sparing healthy tissue. The design of ADCs allows for...
View ArticleRethinking ADC Design: Lessons from NBE-002 and the Potency of PNU-159682
Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted cancer therapeutics, combining the specificity of monoclonal antibodies with the cytotoxicity of potent payloads. The...
View ArticleTROP-2 and the Promise and Peril of High-Affinity in ADCs
Over the last decades, Antibody–drug conjugates (ADCs) have emerged as a transformative class of cancer therapeutics, offering the promise of targeted cytotoxicity with the precision of monoclonal...
View ArticleAntibody-Drug Conjugates in Oncology: Why Potency Is No Longer the Limiting...
Antibody-drug conjugates (ADCs) have transitioned from experimental constructs to a clinically validated therapeutic class, with a rapidly expanding portfolio of approvals across hematologic and solid...
View ArticleHow CDMOs Can Unlock One-step, High-Yield and Homogeneous ADC Manufacturing
The antibody-drug conjugate (ADC) landscape is at a critical inflection point, where manufacturing complexity threatens to stifle innovation amid unprecedented market demand. With over 210 ADCs in...
View ArticleCan Precision ADC Therapy Overcome Current Barriers in AML?
Acute Myeloid Leukemia (AML) is a heterogeneous and highly aggressive hematologic malignancy characterized by a wide range of cytogenetic and molecular abnormalities that define distinct disease...
View ArticleClik here to view.
Reviewing the Key Trends and Insights from the ADC Linker & Conjugation Summit
Antibody drug conjugates (ADCs) continue to dominate the precision oncology field. They traditionally combine monoclonal antibodies specific to surface antigens present on tumour cells with highly...
View ArticleClik here to view.
Takeaways from the 3rd Antibody-Drug Conjugate (ADC) Toxicity Summit
The 3rd Antibody-Drug Conjugate (ADC) in Boston, MA, brought together a group of diverse yet deeply specialized experts who shared their knowledge, clinical insights, and technical experience with...
View ArticleThe Opportunity to go Beyond “Chemo on a Stick” ADCs
Antibodies bearing cytotoxic payloads – though not quite the magic bullets once envisioned – have become a part of late-line therapies for many incurable cancers with at least 15...
View ArticleAnalytical Techniques for Antibody-Drug Conjugates: Comprehensive Insights
Antibody-drug conjugates (ADCs) are a cutting-edge class of biopharmaceuticals that combine the selectivity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. This targeted...
View ArticleRecent Trends of ADCs
Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer therapeutics, offering significant advancements over traditional treatments. The global ADC market is...
View ArticleExo-Linker: Positional Reconfiguration Driving Significant Advances in ADC...
Antibody-drug conjugates (ADCs) have transformed targeted cancer therapy by combining the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. However, payload...
View ArticleClik here to view.
Methodology for assessing Repligen ProStream® and HyStream® Tangential Flow...
Antibody-drug conjugates (ADCs) is a growing field requiring specific handling due to the highly potent drug or highly active pharmaceutical ingredient (HAPI). The generic ADC process is composed of...
View ArticleClik here to view.
The Highs, Lows, and Resurgence of Antibody-drug Conjugates
Antibody-drug conjugates (ADCs) offer a way to deliver a cytotoxic or an immuno-stimulatory payload directly to tumors to maximize the anti-tumor efficacy of the payload with reduced systemic...
View ArticleClik here to view.
Validation of ADC Platform for Protein Concentration and the Drug-Antibody...
Antibody Drug Conjugates (ADCs) are biopharmaceutical drugs which are designed to treat cancer by targeting and killing the cancerous cells while leaving the healthy tissue intact. ADCs are comprised...
View ArticleUnlocking the Potential of Antibody-drug Conjugates
One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He envisioned that a drug could specifically target a...
View ArticleClik here to view.
AJICAP Second-generation: Realizing Versatility and Robustness through...
Abstract Over the past decade, site-specific chemical conjugation has emerged as a promising strategy to produce antibody-drug conjugates (ADCs) in the field of oncology [1]. Daiichi-Sankyo’s chemical...
View ArticleClik here to view.
Bioconjugation Technology Selection during Early-Stage Development – A...
Abstract Bioconjugate therapeutics comprise a fast-growing class of drugs with applications in various disease areas. In the past years, particularly antibody-drug conjugates (ADCs) have undergone a...
View ArticleClik here to view.
How Process Enabling Closed Systems Offer Maximum Safety in ADC Manufacturing
Since Antibody-drug Conjugates (ADC) are already approved for the treatment of relapsed Hodgkin’s lymphoma, HER2-positive metastatic breast cancer and B cell lymphoma, among others, high expectations...
View Article
![ONEW – KAKERA -Unmei no Piece- – EP [iTunes Plus M4A]](http://is1-ssl.mzstatic.com/image/thumb/Music221/v4/d0/fb/86/d0fb86a5-ba60-4bea-41fb-7f54c125f518/VEATP-45908.jpg/296x296bb.webp)
/pic9814888.png)
